Carol M Kao, Christina A Rostad, Lauren E Nolan, Etza Peters, Jennifer Kleinhenz, Jacob D Sherman, Ashley Tippett, J Wai Kuo Shih, Inci Yildirim, Vivien Agbakoba, Tatiana Beresnev, Cassandra Ballou, Satoshi Kamidani, Vinit Karmali, Muktha Natrajan, Erin M Scherer, Nadine Rouphael, Evan J Anderson
INTRODUCTION: Establishing the safety and immunogenicity of a hepatitis E virus vaccine in multiple populations could facilitate broader access and prevent maternal and infant mortality. METHODS: We conducted a phase 1, randomized, double-blinded, placebo-controlled (4:1 vaccine: placebo) trial of 30 µg HEV-239 (Hecolin®, Xiamen Innovax Biotech Company Limited, China) administered intramuscularly in healthy US adults aged 18-45 years. Participants were vaccinated on days 1, 29, and 180...
March 27, 2024: Journal of Infectious Diseases